The Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information on brain tumor chemotherapy research. This book represents the most complete, single-volume resource available for information on the subject of brain tumor chemotherapy. Including a multidisciplinary approach, this volume combines recent advances in tumor therapy with molecular biology, molecular therapeutics, immunobiology, and immunotherapy approaches in one compilation. Chapters new to this volume include cutting-edge research on the molecular underpinnings of brain tumors such as glioblastoma and other gliomas, and the targeted molecular therapies to consider for treatment.
Section 1: PHARMACOLOGICAL AND CLINICAL APPLICATIONS
Section 2: INNOVATIVE CHEMOTHERAPY DELIVERY
Section 3: MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS
Section 4: CHEMOTHERAPY SPECIFIC TUMORS ADULTS
Section 5: CHEMOTHERAPY SPECIFIC TUMORS PEDIATRICS
Section 6: IMMUNOTHERAPY FOR BRAIN TUMORS
Section 7: RESPONSE ASSESSMENT, QUALITY OF LIFE, NEUROPSYCHOLOGY, AND NEW
FRONTIERS
Herbert B. Newton Dr. Newton is currently the Director of the Neuro-Oncology Center and Brain Tumor Institute at the University Hospitals of Cleveland Medical Center and Seidman Cancer Center. He holds the William B. Risman Endowed Chair for Memory and Cognition. He retired as a Professor of neurology and neurosurgery at the Ohio State University Medical Center and the James Cancer Hospital, and was the holder of the Esther Dardinger Endowed Chair in Neuro-Oncology. He trained in neuro-oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan Kettering Cancer Center in New York and has been in academic neuro-oncology for over 30 years. He has published more than 230 peer-reviewed articles and book chapters and is the Chief Editor or Co-Editor of 13 textbooks in the field of neurology and neuro-oncology. In addition, he has been listed as a Best Doctor (neurology) and Top Doctor for cancer (neuro-oncology) for the past 23 years .
